Cost-effectiveness analysis of cefoperazone sulbactam sodium in nosocomial infection

VernacularTitle:头孢哌酮舒巴坦钠在院内感染应用中的成本效益分析
Author: Yuelan SONG ; Jianbing WANG ; Liping LIU
Keywords: Cefoperazone sulbactam sodium; nosocomial infection; cost-effectiveness
From: Chinese Journal of Biochemical Pharmaceutics 2017;37(7):342-343
CountryChina
Language:Chinese
Abstract: Objective To investigate the cost-effectiveness of cefoperazone sulbactam sodium in treating nosocomial infection (lower respiratory tract infection).Methods 80 cases of nosocomial infection in Jincheng Second People's Hospital from January 2014 to January 2017 were treated as the subjects: the observation group was treated with cefoperazone sulbactam sodium and the control group was treated with cefodizime sodium.The data of two groups of patients were recorded and the data were analyzed statistically.The cost-effectiveness of cefoperazone sulbactam sodium in hospital infection was discussed.Results There was no significant difference in the clinical curative effect between the two groups.The cost of observation group (cefoperazone sulbactam sodium) was lower than that of the control group (cefodizime sodium), the difference was statistically significant (P< 0.05).Conclusion Patients with nosocomial infection choose to use cefoperazone sulbactam sodium as the treatment method, which has exact clinical efficacy, high cost-effectiveness.It is worthy of clinical wide application.